# A multicentre randomized double blind placebo controlled trial of myocardial angiogenesis using VEGF165 intramyocardial gene delivery in patients with severe angina pectoris

Submission date 05/09/2005	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
Registration date 05/09/2005	<b>Overall study status</b> Completed	<ul><li>Statistical analysis plan</li><li>Results</li></ul>
Last Edited 18/04/2008	<b>Condition category</b> Circulatory System	<ul><li>Individual participant data</li><li>Record updated in last year</li></ul>

**Plain English summary of protocol** Not provided at time of registration

# **Contact information**

#### **Type(s)** Scientific

**Contact name** Dr Duncan John Stewart

#### **Contact details**

St. Michael's Hospital Division of Cardiology 30 Bond Street Suite 6-050k Queen Wing Toronto Canada M5B 1W8 +1 416 8645724 stewartd@smh.toronto.on.ca

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

#### ClinicalTrials.gov number

Secondary identifying numbers UCT-51532

### Study information

Scientific Title

Acronym Northern trial

#### **Study objectives**

To demonstrate the clinical efficacy and safety of vascular endothelial growth factor (VEGF165) when delivered by direct myocardial injection through the NOGA navigational catheter, to improve myocardial perfusion in patients with severe angina pectoris for whom conventional percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) are either not possible or not ideal. Secondary objective will be to determine the effects of VEGF gene therapy on angina symptoms, patient-perceived quality of life and exercise capacity.

Ethics approval required

Old ethics approval format

**Ethics approval(s)** St. Michael's Hospital Research Ethics Board Office of Research Administration, 12/06/2002

**Study design** Multicentre randomized double blind placebo controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Treatment

Participant information sheet

#### Health condition(s) or problem(s) studied Coronary artery disease with severe angina

#### Interventions

Randomisation NOGA Catheter Mapping and Administration of Gene Therapy. The NOGA catheter will be passed into the left ventricle across the aortic valve and endocardial mapping

carried out. Once the endocardial map is complete, an injection catheter will be introduced into the left ventricle. Patients will be randomly assigned to receive 2 mg of either plasmid DNA encoding the gene for VEGF 165 suspended in phosphate buffered saline or placebo (phosphate buffered saline) in 10 divided injection sites spaced at least 1 cm apart. Injections will be targeted to regions of ischaemia identified by nuclear imaging which correlate with electromechanical NOGA map.

#### Intervention Type

Other

#### Phase

Not Specified

#### Primary outcome measure

Myocardial perfusion - Rest and Stress perfusion Scores (SRS), changes in Summed Stress Scores (SSS) from baseline to 12 weeks follow-up between placebo and VEGF treated groups; this analysis will be repeated at 6 months.

#### Secondary outcome measures

1. Symptom evaluation (Canadian Cardiovascular Society [CCS] class Seattle Angina Questionnaire)

2. Patient-perceived Quality of Life (36-item Short Form health survey [SF-36] questionnaire)

3. Exercise performance

4. Major Adverse Cardiac Events

### Overall study start date

01/08/2002

#### **Completion date**

31/12/2006

# Eligibility

#### Key inclusion criteria

1. Canadian Cardiovascular Class III or IV angina, despite treatment with maximal medical therapy (at least 2 of either long acting nitrates, beta-blockers or calcium channel blockers, and either aspirin or clopidogrel) for at least 4 weeks

2. Adequate secondary prevention medication and risk factor management optimized

3. Ischemic defects on myocardial stress SPECT imaging (include patients with a non-reversible defect having evidence of viability [echo, or other suggestion of wall motion])

- 4. Left Ventricular Ejection Fraction (LVEF) greater than or equal to 20%
- 5. Aged less than or equal to 75 years, either sex
- 6. Adequate feeder coronary vessels to the territories targeted for injection
- 7. LV wall thickness greater than 0.9 cm in target region (by echo)
- 8. Coronary angiography performed within the past 12 months

9. Coronary angiogram shows at least one inflow vessel without a proximal lesion greater than 70%

#### Participant type(s)

Patient

**Age group** Adult

**Sex** Both

Target number of participants

120

#### Key exclusion criteria

1. Pregnancy, lactation, or any childbearing potential

2. Evidence of or a known history of cancer within the past 10 years (except for low grade and fully resolved non-melanoma skin cancer)

3. History or diagnosis of age-related macular degeneration (age-related eye disease study [AREDS]) class 3 or higher

4. Abnormal retinal vascularity (mild, moderate, or sever non-proliferative retinopathy or proliferative retinopathy, or hypertensive hemorrhages or exudates)

5. History of diagnosis of rheumatoid arthritis

6. History of an explained gastrointestinal hemorrhage within the last 5 years

7. Hypervascular dermatologic disease (spider angioma, psoriasis etc.)

8. Serum creatinine, Liver Function Tests (LFTs), or Prothrobin (PT)/Partial Thromboplastin Time (PTT) greater than two times normal

9. Creatine Phosphokinase (CPK) greater than two times Upper Limit of Normal (ULN)

10. Haematocrit (HCT) 30% or Haemoglobin (Hb) less than 100 g/l, platelet count less than 75,000

11. Bleeding diathesis

12. Other severe concurrent illness

13. Ejection Fraction (EF) less than 20%

14. New York Heart Association (NYHA) class greater than 2

15. Single vessel disease involving either the left main or proximal left anterior descending artery for patients in Group 2

16. Recent (within 4 weeks) Myocardial Infarction (MI) (Creatine Kinase Myocardial Bands [CK-MB] greater than 3 x ULN)

17. Uncontrolled hypertension (Systolic Blood Pressure [SBP] greater than 200, or Diastolic Blood Pressure [DBP] greater than 110 mmHg)

18. Persistent atrial fibrillation (must be in NSR at time of NOGA mapping)

19. Frequent, recurrent or sustained ventricular arrhythmias

20. Left ventricular thrombus visualised by either echocardiography or contrast LV angiography 21. Primary valvular heart disease (i.e. AS, MS associated with chest pain)

22. Important aortic valve sclerosis or aortic valve sclerosis or aortic stenosis moderate in severity or greater, which might impede easy catheter access to the left ventricle across the aortic valve

23. Important ilio-femoral peripheral vascular disease limiting catheter access

24. Concurrent enrollment in a study using an experimental drug or procedure

25. Inability to undergo repeat nuclear testing

26. Inability to receive dipyridamole (severe asthma, bronchospasm)

27. Inability to follow the protocol and comply with follow-up

28. Inability to record an adequate NOGA map with at least 50 points and a well defined target area

29. Inability to provide informed consent

Date of first enrolment 01/08/2002

Date of final enrolment 31/12/2006

### Locations

**Countries of recruitment** Canada

Study participating centre St. Michael's Hospital Toronto Canada M5B 1W8

### Sponsor information

**Organisation** St. Michael's Hospital, Toronto (Canada)

**Sponsor details** 30 Bond Street Toronto Canada M5B 1W8

**Sponsor type** Not defined

ROR https://ror.org/04skqfp25

# Funder(s)

**Funder type** Research organisation

#### Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: UCT-51532)

**Funder Name** Heart and Stroke Foundation (Canada)

**Funder Name** Johnson & Johnson (Canada) - 'in-kind' only

### **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration